ACTRN12612000845831
Active, not recruiting
未知
For patients affected by relapsing Idiopathic Retroperitoneal Fibrosis, will treatment with Methotrexate plus Prednisone be effective in achieving and mantaining disease remission.
Augusto Vaglio0 sites15 target enrollmentAugust 13, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Relapsing Idiopathic Retroperitoneal Fibrosis
- Sponsor
- Augusto Vaglio
- Enrollment
- 15
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Diagnosis of relapsing idiopathic retroperitoneal fibrosis and an age between 18 and 85 years.
Exclusion Criteria
- •Pregnancy, active infections or malignancies, known hypersensitivity to the study drugs, uncontrolled diabetes and retroperitoneal fibrosis secondary to known causes.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1/2
Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-BBzeta retroviral vector – A unicenter Phase I/II clinical trial [HD-CAR-1]2024-516832-82-00Universitaetsklinikum Heidelberg AöR63
Completed
Phase 2
Velcade™ (bortezomib) combination chemotherapy in AL amyloidosisISRCTN33283585niversity College London (UCL) (UK)52
Completed
Not Applicable
Intermittent rehabilitation in the therapy of type two diabetesType two diabetesNutritional, Metabolic, EndocrineISRCTN23033749Refonet (Germany)420
Completed
Phase 4
Prehabilitation intervention for patients undergoing elective colectomy: a prospective observational study utilizing a leucine-enriched beveragesarcopeniaJPRN-jRCT1091220321Otsuka Pharmaceutical Factory,Inc.80
Active, not recruiting
Phase 1
A clinical study to provide the opportunity to be treated with CTL019, an investigational gene therapy, for children and adolescent patients with a recurrent form of B-cell acute lymphoblastic leukaemia after the closure of the Novartis single-arm phase II pivotal registration trial (Study CCTL019B2202) and to collect additional safety information.Paediatric/young adult patients with B-cell acute lymphoblastic leukaemia who are chemo-refractory, relapsed after allogeneic SCT, or are otherwise ineligible for allogeneic SCT.MedDRA version: 19.1 Level: LLT Classification code 10063625 Term: Acute lymphoblastic leukemia recurrent System Organ Class: 100000004864MedDRA version: 19.1 Level: LLT Classification code 10063621 Term: Acute lymphoblastic leukaemia recurrent System Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2016-001991-31-ESovartis Farmacéutica, S.A.55